Hepatitis C is a viral infection of the liver caused by the hepatitis C virus (HCV). In the United States, 25 000 to 30 000 new infections occur each year. It is a slowly progressive liver disease, usually without symptoms, that may take 20 to 30 years to cause serious liver damage. About three quarters of persons infected with this virus develop chronic (long-term) hepatitis (inflammation of the liver). An estimated 2.7 million to 3.4 million Americans are chronically infected and 12 000 deaths per year are attributed to the medical complications related to hepatitis C. HCV has become the major cause of liver disease leading to cirrhosis (scarring of the liver) and liver cancer and is now the most frequent indication for liver transplantation.
There are 6 major types (strains) of hepatitis C, referred to as genotypes (based on DNA sequences). The most common genotype in the United States is genotype 1. In 1992, a blood test was discovered and implemented to identify individuals exposed to HCV and to screen blood donors. Knowing the genotype of the virus can have important consequences regarding care. The February 21, 2007, issue of JAMA includes an article about various tests for the diagnosis of HCV infection. These tests provide critical information for guiding treatment and measuring the response to therapy.
HCV is spread primarily by direct contact with the blood of an HCV-infected person. It is not spread by sneezing, hugging or kissing, coughing, breastfeeding, food or water, or other casual contact. There is no vaccine to prevent the infection or spread of HCV.
Most individuals who are newly infected or chronically infected with HCV do not have symptoms. If present, the symptoms may be very mild, nonspecific, and intermittent. They may be flu-like, including fatigue, poor appetite, nausea, muscle and joint pain, or a mild discomfort in the area of the liver.
Ever injected illegal drugs
Received clotting factors made before 1987
Received blood or organ transplants before July 1992
Ever were treated with hemodialysis
Have liver disease of uncertain cause
Have a needlestick with HCV-positive blood
Are 12 to 18 months of age and born to a mother who is HCV-positive
Selection of patients for treatment is guided by virus testing (NAT-nucleic acid tests), liver function tests (blood tests), imaging studies (CT scan, MRI, or ultrasound), and liver biopsy.
Peginterferon combined with ribavirin are the 2 antiviral drugs now being used.
Side effects of drug treatment can be serious, and your doctor may suggest that mild cases of hepatitis C infection should be watched carefully instead of treated with drugs.
Periodic blood tests are required to monitor the infection.
Treatment includes eating a well-balanced diet, drinking plenty of fluids, avoiding alcohol, and exercising.
For end-stage liver disease, liver transplantation may be the only treatment option.
American Liver Foundationhttp://www.liverfoundation.org
American Academy of Family Physicianshttp://www.aafp.org
Hepatitis Foundation Internationalhttp://www.hepfi.org
To find this and previous JAMA Patient Pages, go to the Patient Page link on JAMA's Web site at http://www.jama.com. Many are available in English and Spanish. A Patient Page on hepatitis A was published in the July 13, 2005, issue; and one on hepatitis B was published in the November 10, 1999, issue.
Sources: American Liver Foundation, American Academy of Family Physicians, Hepatitis Foundation International
The JAMA Patient Page is a public service of JAMA. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA suggests that you consult your physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. To purchase bulk reprints, call 203/259-8724.
TOPIC: INFECTIOUS DISEASES
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Journal of American Medical Association editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.